Concepts (149)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dry Eye Syndromes | 23 | 2022 | 293 | 3.260 |
Why?
|
| Tears | 19 | 2022 | 185 | 2.610 |
Why?
|
| Meibomian Glands | 14 | 2022 | 43 | 1.870 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 5 | 2021 | 84 | 1.420 |
Why?
|
| Contact Lenses, Hydrophilic | 8 | 2020 | 19 | 1.340 |
Why?
|
| Postmenopause | 4 | 2013 | 149 | 1.190 |
Why?
|
| Sjogren's Syndrome | 5 | 2018 | 108 | 0.950 |
Why?
|
| Conjunctiva | 4 | 2021 | 197 | 0.770 |
Why?
|
| Eyelid Diseases | 6 | 2022 | 58 | 0.760 |
Why?
|
| Cosmetics | 3 | 2020 | 12 | 0.740 |
Why?
|
| Eye Proteins | 3 | 2012 | 234 | 0.710 |
Why?
|
| Surface Properties | 7 | 2020 | 83 | 0.710 |
Why?
|
| Cornea | 6 | 2019 | 566 | 0.550 |
Why?
|
| Infrared Rays | 4 | 2018 | 23 | 0.550 |
Why?
|
| Contact Lenses | 4 | 2022 | 40 | 0.510 |
Why?
|
| Silicones | 5 | 2020 | 32 | 0.510 |
Why?
|
| CA-125 Antigen | 1 | 2013 | 14 | 0.400 |
Why?
|
| Conjunctival Diseases | 2 | 2021 | 28 | 0.400 |
Why?
|
| Chalazion | 1 | 2013 | 2 | 0.400 |
Why?
|
| Mucin-1 | 1 | 2013 | 34 | 0.400 |
Why?
|
| Ophthalmoscopy | 1 | 2013 | 31 | 0.390 |
Why?
|
| Epithelial Cells | 2 | 2015 | 900 | 0.370 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 775 | 0.360 |
Why?
|
| Image Enhancement | 1 | 2013 | 172 | 0.360 |
Why?
|
| Corneal Topography | 1 | 2012 | 140 | 0.350 |
Why?
|
| Hydrogels | 3 | 2020 | 101 | 0.340 |
Why?
|
| Eyelids | 4 | 2018 | 108 | 0.320 |
Why?
|
| Muramidase | 1 | 2010 | 89 | 0.320 |
Why?
|
| Lipocalins | 1 | 2010 | 32 | 0.320 |
Why?
|
| Middle Aged | 26 | 2022 | 28888 | 0.320 |
Why?
|
| Surveys and Questionnaires | 11 | 2019 | 4050 | 0.320 |
Why?
|
| Hyperthermia, Induced | 2 | 2022 | 56 | 0.320 |
Why?
|
| Diagnostic Imaging | 3 | 2018 | 300 | 0.310 |
Why?
|
| Optometry | 2 | 2018 | 7 | 0.290 |
Why?
|
| Proteomics | 1 | 2012 | 607 | 0.280 |
Why?
|
| Keratoconjunctivitis Sicca | 1 | 2008 | 50 | 0.270 |
Why?
|
| Female | 32 | 2022 | 71185 | 0.240 |
Why?
|
| Membrane Proteins | 1 | 2013 | 1613 | 0.230 |
Why?
|
| Lipids | 3 | 2015 | 565 | 0.230 |
Why?
|
| Cysts | 1 | 2005 | 93 | 0.220 |
Why?
|
| Young Adult | 16 | 2021 | 10104 | 0.210 |
Why?
|
| Adult | 23 | 2022 | 31719 | 0.210 |
Why?
|
| Humans | 40 | 2022 | 131679 | 0.210 |
Why?
|
| Aged | 15 | 2022 | 21260 | 0.210 |
Why?
|
| Disposable Equipment | 3 | 2020 | 16 | 0.190 |
Why?
|
| Blotting, Western | 3 | 2017 | 1018 | 0.180 |
Why?
|
| Hyperemia | 1 | 2021 | 31 | 0.170 |
Why?
|
| Male | 23 | 2022 | 65266 | 0.170 |
Why?
|
| Lubricant Eye Drops | 2 | 2020 | 10 | 0.170 |
Why?
|
| Goblet Cells | 1 | 2021 | 104 | 0.160 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2021 | 88 | 0.160 |
Why?
|
| Severity of Illness Index | 4 | 2021 | 3101 | 0.160 |
Why?
|
| Prospective Studies | 10 | 2022 | 6494 | 0.150 |
Why?
|
| Skin Cream | 2 | 2015 | 8 | 0.150 |
Why?
|
| Hydrogel, Polyethylene Glycol Dimethacrylate | 2 | 2015 | 25 | 0.140 |
Why?
|
| Patient Dropouts | 1 | 2018 | 50 | 0.140 |
Why?
|
| Visual Acuity | 2 | 2018 | 537 | 0.140 |
Why?
|
| Cathepsins | 1 | 2017 | 26 | 0.130 |
Why?
|
| Proteoglycans | 1 | 2017 | 79 | 0.130 |
Why?
|
| Aged, 80 and over | 6 | 2021 | 6924 | 0.130 |
Why?
|
| Contact Lens Solutions | 1 | 2016 | 5 | 0.130 |
Why?
|
| Population Surveillance | 1 | 2019 | 397 | 0.120 |
Why?
|
| Hygiene | 1 | 2016 | 24 | 0.120 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2016 | 21 | 0.120 |
Why?
|
| Ophthalmic Solutions | 1 | 2016 | 88 | 0.120 |
Why?
|
| Sebum | 1 | 2015 | 2 | 0.110 |
Why?
|
| Microscopy, Atomic Force | 1 | 2015 | 16 | 0.110 |
Why?
|
| Debridement | 1 | 2015 | 90 | 0.110 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2017 | 288 | 0.110 |
Why?
|
| Diagnosis, Differential | 2 | 2013 | 1911 | 0.110 |
Why?
|
| Cytological Techniques | 2 | 2021 | 18 | 0.100 |
Why?
|
| Methacrylates | 1 | 2012 | 16 | 0.100 |
Why?
|
| Fluorescein | 3 | 2019 | 39 | 0.100 |
Why?
|
| Adolescent | 10 | 2022 | 20982 | 0.100 |
Why?
|
| Dietary Supplements | 1 | 2016 | 453 | 0.090 |
Why?
|
| Specimen Handling | 1 | 2013 | 149 | 0.090 |
Why?
|
| Biomedical Research | 1 | 2018 | 556 | 0.090 |
Why?
|
| Staining and Labeling | 3 | 2019 | 172 | 0.090 |
Why?
|
| Contact Lenses, Extended-Wear | 1 | 2011 | 5 | 0.090 |
Why?
|
| Reproducibility of Results | 3 | 2015 | 2989 | 0.090 |
Why?
|
| Eye Diseases | 1 | 2013 | 108 | 0.090 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 530 | 0.080 |
Why?
|
| Lipid Metabolism | 1 | 2012 | 371 | 0.070 |
Why?
|
| Ontario | 2 | 2019 | 87 | 0.070 |
Why?
|
| Spectrophotometry | 1 | 2008 | 55 | 0.070 |
Why?
|
| Silicone Gels | 1 | 2007 | 4 | 0.070 |
Why?
|
| Age Distribution | 2 | 2019 | 429 | 0.070 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 432 | 0.070 |
Why?
|
| Osmolar Concentration | 1 | 2007 | 148 | 0.070 |
Why?
|
| RNA, Messenger | 1 | 2013 | 2568 | 0.060 |
Why?
|
| Time Factors | 2 | 2017 | 6279 | 0.060 |
Why?
|
| Retrospective Studies | 3 | 2020 | 17667 | 0.060 |
Why?
|
| Cross-Sectional Studies | 3 | 2020 | 3834 | 0.060 |
Why?
|
| Remission, Spontaneous | 1 | 2005 | 65 | 0.060 |
Why?
|
| Analysis of Variance | 2 | 2018 | 955 | 0.060 |
Why?
|
| Follow-Up Studies | 3 | 2016 | 5297 | 0.060 |
Why?
|
| Circadian Rhythm | 1 | 2007 | 316 | 0.060 |
Why?
|
| Gene Expression Regulation | 1 | 2013 | 2357 | 0.050 |
Why?
|
| Cohort Studies | 1 | 2013 | 5123 | 0.050 |
Why?
|
| Cross-Over Studies | 2 | 2016 | 331 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2018 | 1454 | 0.050 |
Why?
|
| Tomography, Optical Coherence | 1 | 2007 | 463 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2008 | 3454 | 0.040 |
Why?
|
| Cell Count | 1 | 2021 | 217 | 0.040 |
Why?
|
| Incidence | 2 | 2018 | 3347 | 0.040 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2020 | 73 | 0.040 |
Why?
|
| Prosthesis Fitting | 1 | 2020 | 11 | 0.040 |
Why?
|
| Organ Preservation | 1 | 2021 | 60 | 0.040 |
Why?
|
| Double-Blind Method | 2 | 2016 | 1636 | 0.040 |
Why?
|
| Canada | 1 | 2020 | 327 | 0.040 |
Why?
|
| Optics and Photonics | 1 | 2020 | 106 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 322 | 0.040 |
Why?
|
| Asymptomatic Diseases | 1 | 2018 | 78 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2018 | 241 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2019 | 322 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2019 | 306 | 0.030 |
Why?
|
| North America | 1 | 2018 | 256 | 0.030 |
Why?
|
| Tissue and Organ Procurement | 1 | 2021 | 253 | 0.030 |
Why?
|
| Prognosis | 1 | 2007 | 4952 | 0.030 |
Why?
|
| Lubrication | 1 | 2017 | 1 | 0.030 |
Why?
|
| Friction | 1 | 2017 | 2 | 0.030 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2017 | 260 | 0.030 |
Why?
|
| Eye Pain | 1 | 2016 | 11 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2021 | 2143 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2018 | 469 | 0.030 |
Why?
|
| Lissamine Green Dyes | 1 | 2015 | 8 | 0.030 |
Why?
|
| Coloring Agents | 1 | 2015 | 72 | 0.030 |
Why?
|
| Glycoproteins | 1 | 2017 | 344 | 0.030 |
Why?
|
| Atrophy | 1 | 2015 | 251 | 0.030 |
Why?
|
| Vision Disorders | 1 | 2016 | 197 | 0.030 |
Why?
|
| Risk Factors | 2 | 2019 | 10959 | 0.030 |
Why?
|
| Disease Progression | 1 | 2020 | 2206 | 0.030 |
Why?
|
| Fluorescent Dyes | 1 | 2015 | 251 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2017 | 1316 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 1626 | 0.030 |
Why?
|
| Observer Variation | 1 | 2014 | 319 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2017 | 2564 | 0.020 |
Why?
|
| Electrophoresis | 1 | 2012 | 38 | 0.020 |
Why?
|
| X-Ray Diffraction | 1 | 2012 | 101 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2017 | 3616 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2012 | 291 | 0.020 |
Why?
|
| Radiography | 1 | 2014 | 762 | 0.020 |
Why?
|
| Age Factors | 1 | 2018 | 2872 | 0.020 |
Why?
|
| Equipment Contamination | 1 | 2011 | 42 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2011 | 334 | 0.020 |
Why?
|
| Prosthesis Design | 1 | 2012 | 612 | 0.020 |
Why?
|
| Protein Binding | 1 | 2012 | 1712 | 0.020 |
Why?
|
| Quality of Life | 1 | 2016 | 2118 | 0.020 |
Why?
|
| Child | 1 | 2020 | 26299 | 0.010 |
Why?
|